

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 4th August 2025

FOI Ref No 29811

Requested Information:

1. How many patients were treated in the last 4 months (April to July 2025) by the dermatology department with each of the following products:

- Abrocitinib
- Acitretin
- Alitretinoin
- Azathioprine
- Baricitinib
- Ciclosporin
- Dupilumab
- Lebrikizumab
- Methotrexate
- Mycophenolate mofetil
- Pimecrolimus
- Phototherapy (UVB or PUVA) - for Atopic Dermatitis only
- Tacrolimus ointment
- Tralokinumab
- Upadacitinib
- Nemolizumab

2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department

- Abrocitinib
- Baricitinib
- Dupilumab
- Lebrikizumab
- Tralokinumab
- Upadacitinib
- Nemolizumab

*Patients are considered initiated on a treatment if they have not been treated with the named treatment in the previous 8 months.

3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

- 6 months to 5
- Age 6-11
- Age 12-17
- Age 18 and above

Response:

1. How many patients were treated in the last 4 months (April to July 2025) by the dermatology department with each of the following products:

- Abrocitinib **12**
- Acitretin **83**
- Alitretinoin **4**
- Azathioprine **8**
- Baricitinib **1**
- Ciclosporin **15**
- Dupilumab **157**
- Lebrikizumab **3**
- Methotrexate **133**
- Mycophenolate mofetil **7**
- Pimecrolimus **84**
- Phototherapy (UVB or PUVA) - for Atopic Dermatitis only **18**
- Tacrolimus ointment **65**
- Tralokinumab **32**
- Upadacitinib **10**
- Nemolizumab **0**

2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department

- Abrocitinib **0**
- Baricitinib **0**
- Dupilumab **18**
- Lebrikizumab **0**
- Tralokinumab **7**
- Upadacitinib **1**
- Nemolizumab **0**

*Patients are considered initiated on a treatment if they have not been treated with the named treatment in the previous 8 months.

3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

- 6 months to 5
- Age 6-11
- Age 12-17
- Age 18 and above

- Abrocitinib
 - Age 18 and above: **12**
- Acitretin
 - Age 18 and above: **83**
- Alitretinoin

- Age 18 and above: **4**
- Azathioprine
 - Age 12-17: **1**
 - Age 18 and above: **7**
- Baricitinib
 - Age 18 and above: **1**
- Ciclosporin
 - 6 months to 5: **1**
 - Age 6-11: **2**
 - Age 12-17: **2**
 - Age 18 and above: **10**
- Dupilumab
 - 6 months to 5: **1**
 - Age 6-11: **5**
 - Age 12-17: **11**
 - Age 18 and above: **140**
- Lebrikizumab
 - Age 18 and above: **3**
- Methotrexate
 - 6 months to 5: **2**
 - Age 6-11: **11**
 - Age 12-17: **26**
 - Age 18 and above: **94**
- Mycophenolate mofetil
 - Age 12-17: **1**
 - Age 18 and above: **6**
- Pimecrolimus
 - 6 months to 5: **19**
 - Age 6-11: **15**
 - Age 12-17: **11**
 - Age 18 and above: **39**
- Phototherapy (UVB or PUVA) - for Atopic Dermatitis only
 - Age 18 and above: **18**
- Tacrolimus ointment
 - 6 months to 5: **7**
 - Age 6-11: **4**
 - Age 12-17: **13**
 - Age 18 and above: **41**
- Tralokinumab
 - Age 12-17: **1**
 - Age 18 and above: **31**
- Upadacitinib
 - Age 18 and above: **10**
- Nemolizumab **0**



Royal Cornwall Hospitals
NHS Trust

Attachment(s):

No Attachment(s)

Date Response sent: 8th August 2025